Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity

Neuropharmacology

Volumn 44, Issue 6, 2003, Pages 773-786

  Yao, B B ^a   Hutchins, C W ^a   Carr, T L ^a   Cassar, S ^a   Masters, J N ^a   Bennani, Y L ^a   Esbenshade, T A ^a   Hancock, A A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

GPCR; Histamine H3 receptor; Molecular modeling; Mutagenesis; Signal transduction; Species selectivity

Indexed keywords

2 AMINO 1 [4 [3 (4 CYCLOPROPANECARBONYLPHENOXY)PROPYL] 1 PIPERAZINYL] 1 PROPANONE; 2 AMINO 1 [4 [3 (4 CYCLOPROPANECARBONYLPHENOXY)PROPYL]PIPERAZIN 1 YL]PROPAN 1 ONE; 4 [2 (5,5 DIMETHYL 1 HEXYNYL)CYCLOPROPYL] 1H IMIDAZOLE; ALPHA METHYLHISTAMINE; CIPROXIFAN; CLOBENPROPIT; COMPLEMENTARY DNA; CYCLOPROPANE DERIVATIVE; GT 2331; HISTAMINE; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; IMOPROXIFAN; THIOPERAMIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR CLONING; MOLECULAR MODEL; MOLECULAR RECOGNITION; MUTAGENESIS; NEUROTRANSMITTER RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

EID: 0037401965     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00056-X     Document Type: Article

References (35)

1. 3-receptors. Nature. 327:1987;117-123.
2. Ballesteros J.A., Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 25:1995;366-428.
3. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18:1999;1723-1729.
4. Boyd S.A., Mantei R.A., Tasker A.S., Liu G., Sorensen B.K., Henry K.A. Jr, von Geldern T.W., Winn M., Wu-Wong J.R., Chiou W.J., Dixon D.B., Hutchins C.W., Marsh K.C., Nguyen B., Opgenorth T.J. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ETA receptor selectivity. Bioorg and Med Chem. 7:1999;991-1002.
5. 3 receptor. Neuroreport. 11:2000;L3-4.
6. 35S]GTPγ[S] binding to pertussis toxin. Eur J Pharmacol. 296:1996;223-225.
7. 3 receptor. Biochem J. 355:2001;279-288.
8. iα Nature. 363:1993;274-276.
9. 3 receptor isoforms with different brain expression and signaling properties. Mol Pharmacol. 59:2001;1-8.
10. 2+ channels. J Pharmacol Exp Ther. 269:1993;221-229.
11. Esbenshade T.A., Hancock A.A. Characterization of histamingergic receptors. Enna S.J., Williams M., Ferkany J.W., Porsolt R.D., Kenakin T., Sullivan J.P. The Protocols of Pharmacology. 2000;1 John Wiley & Sons, New York.
12. Esbenshade, T.A., Krueger, K., Denny, L.I., Miller, T., Kang, C.H., Witte, D., Yao, B., Black, L., Bennani, Y.L., Fox, G.B., Pan, J.B., Decker, M.W., Hancock, A., 2001. Complex pharmacological effects of GT-2331. Society for Neuroscience 31st Annual Meeting 26, 378.11.
13. 3 receptor ligands. Part 2: binding preference for D-amino acids motifs. Bioorg Med Chem Lett. 12:2002;2035-2037.
14. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pop. Behav Brain Res. 131:2002;151-161.
15. Goodearl, A.D.J., 1999. Nucleic acids encoding muscarinic receptors and uses therefore. US Patent # 5,882,893.
16. Goodearl, A.D.J., Glucksman, M.A., 2000. Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors. US Patent # 6,093,545.
17. Hough L.B. Cellular localization and possible functions for brain histamine: Recent progress. Prog Neurobiol. 30:1988;469-505.
18. Hutchins C. Three-dimensional Models of the D1 and D2 Dopamine Receptors. Endocrine J. 2:1994;7-23.
19. 3 receptors. Eur J Pharmacol. 433:2001;141-150.
20. 3 receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 131:2000;1247-1250.
21. Lin J.S., Sakai K., Jouvet M. Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacol. 27:1988;111-122.
22. 3 receptor. Mol Pharm. 55:1999;1101-1107.
23. 3 receptor reveals distinct species pharmacological profiles. J Pharmacol Exp Ther. 293:2000;771-778.
24. Nakamura T., Itadani H., Hidaka Y., Ohta M., Tanaka K. Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun. 279:2000;615-620.
25. Selbie L.A., Hill S.J. G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. Trends Pharmacol Sci. 19:1998;87-93.
26. 3 receptors. Bioorg Med Chem Lett. 11:2001;951-954.
27. Strader C.D., Sigal I.S., Dixon R.A. Structural basis of beta-adrenergic receptor function. FASEB J. 3:1989;1825-1832.
28. 3 receptor: evidence for two isoforms. Neuroreport. 11:2000;755-759.
29. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res. 22:1994;4673-4680.
30. 3 receptor. J Pharmacol Exp Ther. 301:2002;451-458.
31. von Geldern T.W., Hutchins C., Kester J.A., Wu-Wong J.R., Chiou W., Dixon D., Opgenorth T.J. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile. J Med Chem. 39:1996;957-967.
32. Wada H., Inagaki N., Yamatodani A., Watanabe T. Is the histaminergic neuron system a regulatory center for whole-brain activity? Trends Neurosci. 14:1991;415-418.
33. 3 receptor. Neuropharmacol. 42:2002;929-940.
34. 3H]Nα-methylhistamine binding differ from that of rodents. Eur J Pharmacol. 377:1999;233-239.
35. 3 receptor. Society for Neuroscience 31st Annual Meeting 26, 804.3.